[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognition":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,47,80,142,172,193,226,265,287,315,347,379,401,455,485,515,539,574,602,636,658,679,705,728,753],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644913","lion-tracks-eeg-pilot-understand-cognitive-responses-to-crossfit-in-mother-child-dyads-100644913",false,"NCT07677345","Lion Tracks EEG Pilot: Understand Cognitive Responses to CrossFit in Mother-Child Dyads","Lion Tracks EEG Pilot","Lion Tracks","Inclusion Criteria\n\n* Adult participant is a mother or female primary caregiver aged 18 years or older.\n* Child participant is at least 3 years of age.\n* Mother and child are willing to participate together as a dyad.\n* Mother and child are able to understand and speak English.\n* Mother and child are willing to attend two study visits at a participating community fitness facility.\n* Mother and child are able to safely participate in moderate-to-vigorous physical activity as determined by health screening procedures.\n* Mother is willing to provide informed consent and child is willing to provide assent when appropriate.\n\nExclusion Criteria \\*Mother\\*\n\n* Pregnancy at the time of participation.\n* Any cardiovascular, metabolic, respiratory, neurological, musculoskeletal, or other medical condition that would make exercise unsafe.\n* Current injury or physical limitation preventing participation in exercise.\n* History of seizure disorder or other condition that may interfere with EEG assessment.\n* Inability to complete study procedures or wear EEG equipment. \\*Child\\*\n* Medical condition, injury, or physical limitation that would make participation in exercise unsafe.\n* Neurological condition or developmental disorder that would prevent completion of study procedures, as determined by the parent and study team.\n* History of seizure disorder or other condition that may interfere with EEG assessment.\n* Inability to tolerate wearing the EEG headset or complete study procedures. \\*Dyad\\*\n* Either the mother or child is unable or unwilling to complete both study visits.\n* Either participant has a contraindication to exercise identified during screening.\n* Either participant has a condition that, in the opinion of the investigators, would make participation unsafe or compromise data quality.",true,"FEMALE","3 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this study is to examine how participating in exercise together versus separately influences brain function, cognitive performance, mood, and parent-child connection in mother-child dyads. Mothers and their children will complete two fitness class visits at a participating community fitness facility\u002FCrossFit affiliate. During one visit, mothers and children will exercise in separate age-appropriate classes, and during the other visit they will exercise together in a shared class. Before and after each exercise session, participants will complete brief assessments of cognition, mood, and brain activity using a portable electroencephalography (EEG) device. Findings from this pilot study will help determine the feasibility of conducting community-based neuroscience research and may inform future family-centered physical activity programs designed to support brain, emotional, and social health.",[29],"Cognition",[31,32,33,34],"Mother-Child Dyads","CrossFit","Brain Health","Family-Based Physical Activity","NOT_YET_RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":23},"2027-01-01",{"date":43,"type":23},"2028-03-01",{"name":45,"class":46},"Penn State University","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100645002","phase-2-exercise-and-intranasal-insulin-in-type-2-diabetes-100645002","NCT07675499","Exercise and Intranasal Insulin in Type 2 Diabetes","Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes","Inclusion Criteria:\n\n* Male or female 55-80 years old\n* Type 2 diabetes diagnosis or confirmation HbA1c \\>6.5% and fasting glucose \\>126 mg\u002Fdl\n* Individuals prescribed metformin, GLP-1 agonists (oral\u002Finjectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors \\>6 months.\n* MOCA ≥26\n* Body mass index (BMI) ≥25 and ≤40 kg\u002Fm2\n* Not diagnosed with Type 1 diabetes\n* Not currently engaged in \\\u003C90 min\u002Fwk of exercise\n\nExclusion Criteria:\n\n* A diagnosis of dementia\n* Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.)\n* Intolerance to insulin\n* Morbidly obese patients (BMI \\>40 kg\u002Fm2) and lean patients (BMI \\\u003C25 kg\u002Fm2)\n* \\>2 kg weight change in past 6 months\n* Participants who have been recently active (\\>90 min of moderate\u002Fhigh intensity exercise)\n* Individuals who are smokers or who have quit smoking (\\\u003C2 years)\n* Hypertriglyceridemia (400 mg\u002Fdl) and hypercholesterolemic (\\>260 mg\u002Fdl) subjects\n* Uncontrolled Hypertensive (\\>160\u002F100 mmHg)\n* Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Participants with contraindications to participation in an exercise training program\n* Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol\u002Fsubstance abuse)\n* History of head trauma or loss of consciousness in last 5 years.\n* Known contraindications for MR imaging:\n\n  * History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results.\n  * Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted).\n  * Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies.\n  * Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded.\n  * History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask\n  * Lead\u002Firon tattoos\n  * Claustrophobia (history of significant anxiety in closed places).\n  * Back problem that would prevent the subject from laying still comfortably for up to 90 minutes.\n  * Deafness","ALL","55 Years","80 Years",{"count":58,"type":23},60,[60,61],"PHASE2","PHASE3","About 6.5 million adults in the United States who are 65 or older have dementia.\n\nWhile the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.",[64,65,29,66],"Type 2 Diabetes","Insulin Sensitivity\u002FResistance","Brain Blood Flow",[68,69],"Exericse","Intranasal Insulin","RECRUITING","2026-06-26",{"date":36,"type":39},{"date":74,"type":23},"2026-08-03",{"date":76,"type":23},"2029-05-31",{"name":78,"class":46},"Rutgers, The State University of New Jersey",4,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":18,"sex":54,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":24,"phases":91,"briefSummary":92,"conditions":93,"keywords":121,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100454745","interventions-in-mathematics-and-cognitive-skills-100454745","NCT05201534","Interventions in Mathematics and Cognitive Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scle of Intelligence (WASI-II).\n3. Identification of Mathematical Learning Disabilities: Scores below the 35th percentile percentile on symbolic number processing test in Numeracy Screener and two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 35th percentile percentile on symbolic number processing test in Numeracy Screener and all WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder.)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, claustrophobia)","6 Years","12 Years",{"count":90,"type":23},180,[26],"The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).",[94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,29,111,112,113,114,115,116,117,118,119,120],"Math Learning Disability","Child Development","Developmental Disability","Learning Disabilities","Learning Disabled","Learning Curve","Mathematics Disorder","Dyscalculia","Dyscalculia, Primary","Dyscalculia, Acquired","Specific Learning Disorder, With Impairment in Mathematics","Individuality","Behavior, Child","Behavior and Behavior Mechanisms","Behavior","Decision Making","Neuronal Plasticity","Cognition Disorder","Cognitive Dysfunction","Cognitive Change","Cognitive Impairment, Mild","Cognitive Developmental Delay","Cognitive Orientation","Cognitive Delay, Mild","Cognitive Deficits, Mild","Cognitive Abnormality","Neuroscience",[122,123,124,125,126,127,128,129,130,131],"Numerical skills in children","Low math abilities","Mathematical Learning Disabilities","Mathematical Concepts","Mathematics","Transfer, Psychology","Generalization, Psychology","Early Intervention, Educational","Neural Pathways","Neural Networks, Computer","2026-06-22",{"date":134,"type":39},"2026-06-25",{"date":136,"type":39},"2023-05-05",{"date":138,"type":23},"2026-08-31",{"name":140,"class":46},"Stanford University",1,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":24,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":171},"100622819","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-function-at-varying-dosages-in-healthy-younger-adults-with-self-reported-attention-problems-100622819","NCT07388576","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof-of-concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","Inclusion Criteria:\n\n1. Males and females 18-39 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported focus or attention problems, as determined by QI assessment of the Adult Attention Deficit Hyperactivity Disorder Self-Report Scale (Part A) (ASRS; version 1.1) (20)\n4. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n5. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n6. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n7. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n8. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n9. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n10. Provided voluntary, written, informed consent to participate in the study\n11. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Clinical diagnosis and\u002For prescribed treatment for ADHD (See Section 7.3.1)\n4. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., autism spectrum disorder, schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n5. Self-reported color blindness\u002Fweakness as assessed by the QI\n6. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n7. Current employment that calls for overnight shiftwork as assessed by the QI\n8. Unstable metabolic disease or chronic diseases as assessed by the QI\n9. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n10. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n11. Type I diabetes\n12. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n13. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n14. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n15. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n21. Use of medical cannabinoid products\n22. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n23. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n24. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n25. Alcohol or drug abuse within the last 12 months\n26. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n27. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n28. Clinically significant abnormal laboratory results at screening as assessed by the QI\n29. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n30. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n31. Individuals who are cognitively impaired and\u002For unable to give informed consent\n32. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","18 Years","39 Years",{"count":152,"type":23},120,[26],"The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive function at varying dosages in healthy younger adults with self-reported attention problems.\n\nThe main question it aims to answer is what Change from baseline to Day 56 between AP-Brain (1g, 3g, or 5g) and placebo in cognitive function, as assessed by the CNS VS Neurocognitive Index (NCI) score and complex attention.\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[29,156],"Cognitive Function",[158,159,160],"memory","cognitive function","AP-Brain","2026-06-19",{"date":163,"type":39},"2026-06-24",{"date":165,"type":23},"2026-06",{"date":167,"type":23},"2026-11",{"name":169,"class":170},"Rousselot BVBA","INDUSTRY",2,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":18,"sex":54,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":192,"locationsCount":171},"100622778","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-performance-at-varying-dosages-in-healthy-middle-aged-and-older-adults-with-self-reported-memory-problems-100622778","NCT07388043","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof of Concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","Inclusion Criteria:\n\n1. Males and females 40-79 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported memory problems as assessed by a combined score of ≥6 from the memory assessment questions provided at screening\n4. Absence of dementia or other significant cognitive impairment as assessed by MMSE-2 score of ≥24 at screening\n5. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n6. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n7. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n8. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n9. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n10. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n11. Provided voluntary, written, informed consent to participate in the study\n12. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., attention-deficit\u002Fhyperactivity disorder, Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n4. Self-reported color blindness\u002Fweakness as assessed by the QI\n5. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n6. Current employment that calls for overnight shiftwork as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n10. Type I diabetes\n11. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n16. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n17. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n18. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n19. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n20. Use of medical cannabinoid products\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n26. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n27. Clinically significant abnormal laboratory results at screening as assessed by the QI\n28. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n29. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n30. Individuals who are cognitively impaired and\u002For unable to give informed consent\n31. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","40 Years","79 Years",{"count":152,"type":23},[26],"The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive performance at varying dosages in healthy middle-aged and older adults with self-reported memory problems. The main question it aims to answer is:\n\nWhat is the effect of AP-Brain at 1 g, 3 g, and 5 g on cognitive performance?\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[29,185],"Cognitive Performance",[187,160,188],"Memory","cognitive performance",{"date":163,"type":39},{"date":165,"type":23},{"date":167,"type":23},{"name":169,"class":170},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":214,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100613164","phase-3-cognitive-strategies-in-early-psychosis-2-100613164","NCT07263022","Cognitive Strategies in Early Psychosis 2","COSTEP 2","Inclusion Criteria:\n\n* Between the ages of 18 and 35\n* Onset of a psychosis spectrum illness (schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis NOS, bipolar disorder with psychosis, or major depressive disorder with psychosis) within 5 years of enrollment\n* Estimated IQ of 70 or above\n* Proficient at English as determined through interactions with the study team\n* No change in psychiatric medication within a week of enrollment or MRI study visits\n* No clinically significant change in any medications for at least 1 month prior to study participation or MRI study visits, as determined by PI\u002FCo-Is\n\n  * Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have had major increases or decreases in doses, or additions or removal of medication within the past 30 days.\n  * Participants are to have no changes to medications in the past 7 days before drug administration (i.e., must have been on a stable dose for at least 7 days prior to receiving the study drug).\n\nExclusion Criteria:\n\nMedical Criteria:\n\n* Presence of the following medical concerns as determined by the study PI:\n\n  * Major neurological disorder\n  * History of a clinically significant head injury with or without prolonged unconsciousness\n  * Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk by participating\n* History of any of the following as reported by the participant:\n\n  * Renal impairment, injury, or disease\n  * Hepatic impairment, injury, or disease\n  * Myocardial infarction or heart disease, or endorsement of history of or of cardiac symptoms at intake:\n\n    * Dyspnea\n    * Palpitations\n    * Orthopnea\n    * Pedal oedema\n    * Significant dizziness\n    * Syncope\n    * Claudication\n  * Low white blood cell count, or is diagnosed with leukopenia, neutropenia, or agranulocytosis\n* Presence of unmanaged hypertension (\\>140\u002F90) or elevated resting heart rate (\\>100 bpm)\n* Abnormal clinical laboratory values:\n\n  * uACR \\> 30 mg\u002Fg\n  * creatinine level \\>0.95 mg\u002FdL\n  * AST or ALT \\> 50 U\u002FL\n  * Bilirubin \\> 1.2 mg\u002FdL\n  * Total Protein \\\u003C 6 g\u002FdL\n* Taking a medication or supplement that has a major drug interaction with any study drugs (e.g., ketamine, MAOIs, clomipramine, diazepam, propranolol, warfarin)\n* Allergies to study drugs\n* Is pregnant, planning to become pregnant, or is breastfeeding\n* Cannot pass the visual acuity test\n* Cannot pass the CMRR Subject Safety Screen due to MRI contraindications\n\nMental health criteria:\n\n* Meets criteria for a severe substance or alcohol use disorder within 3 months of enrollment\n* Lifetime history of a stimulant use disorder\n* Current manic episode as determined by the MINI\n* History of psychiatric hospitalization within 3 months of enrollment\n* Meets criteria for clinical risk of suicidal behavior, as defined by:\n\n  * Clinician judgment\n  * A suicide attempt within 3 months of enrollment\n  * Active suicidal ideation at screening or baseline, as indicated by the C-SSRS Screener\n  * Previous intent to act on suicidal ideation with a specific plan and\u002For preparatory acts within 3 months of enrollment, as indicated by the C-SSRS Screener\n* Symptom severity scores in the severe (6) or extremely severe (7) range on the BPRS for the following items: suicidality, disorientation, bizarre behavior, excitement, elevated mood\n* Any other psychiatric symptoms or conditions that, in the opinion of the PI, would impede participation in the study or put the participant at additional risk by participating\n\nOther criteria:\n\n* Unable or unwilling to provide informed consent\n* Unable to demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in the research study\n* Current guardianship\n* Is under civil commitment or under a stay of civil commitment\n* Illiteracy\n* Has engaged in significant cognitive training, in the opinion of the PI, in the last year","35 Years",{"count":202,"type":23},24,[61],"The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last five years. The investigators will study how two study agents change decision making in people with psychosis, by asking participants to complete some brain games on the computer before and after taking the study agents. The investigators hope to improve our understanding of psychosis to help people in the future. The main research questions are:\n\n* Does a single dose of modafinil change how people with psychosis play the brain games?\n* Does a single dose of d-serine change how people with psychosis play the brain games?\n* Does a single dose of modafinil change brain activity?\n* Does a single dose of d-serine change brain activity?\n\nParticipants will:\n\n* Complete an interview and self-report questionnaires.\n* Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test.\n* Complete functional Magnetic Resonance Imaging (fMRI) scans. fMRI uses magnets to take pictures of the brain. There will be six scanning appointments in the study, with two scans each. Appointments will be about a month apart.\n* Take a single dose of a study agent during each scanning appointment. The study agent will be taken after the first fMRI. There are three study agents in total: modafinil, d-serine, and a placebo. Each participant will take each study agent twice during the study.\n* Play brain games on a computer that measure decision making, thinking, and problem solving skills",[206,207,208,209,210,211,212,213,29],"Psychosis","Schizophrenia Disorder","Schizoaffective Disorder","Major Depressive Disorder With Psychotic Features","Bipolar Disorder With Psychotic Features","Psychosis NOS","Schizophreniform Disorder","Psychotic Disorder",[29,109,215,216],"fMRI","Psychosis spectrum disorders","2026-05-28",{"date":219,"type":39},"2026-05-29",{"date":221,"type":23},"2026-07-07",{"date":223,"type":23},"2030-04-30",{"name":225,"class":46},"University of Minnesota",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":24,"phases":236,"briefSummary":237,"conditions":238,"keywords":247,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":141},"100640612","flumazenil-for-benzodiazepine-reversal-in-electroconvulsive-therapy-100640612","NCT07619092","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial","FLEET","Inclusion criteria:\n\n* Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33.\n* Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark\n* Referred to ECT by the regular psychiatrist and has given consent to ECT\n* Currently receiving treatment with a benzodiazepine and\u002For zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam.\n\nExclusion criteria:\n\n* Involuntary treatment with ECT\n* Known gross abnormalities in brain structure deemed likely to influence cognitive functioning\n* Pregnancy or breast-feeding\n* Inability to read or understand Danish\n* Acute organic brain disease (e.g., delirium) influencing the ability to give informed consent\n* Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states\n* Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)",{"count":235,"type":23},145,[26],"The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and\u002For zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression.\n\nThe investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes).\n\nInvestigators will compare two different pre-ECT benzodiazepine management strategies:\n\n1. Flumazenil strategy (experimental): continued benzodiazepine and\u002For zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT\n2. Benzodiazepine withholding strategy (treatment as usual):\n\ndiscontinuation of benzodiazepines and\u002For zopiclone prior to the ECT in accordance with standard clinical practice",[239,240,241,29,242,243,244,245,246],"Depression - Major Depressive Disorder","Bipolar Disorder (BD)","Functional Magnetic Resonance Imaging (fMRI)","Autobiographical Memory","Electroconvulsive Therapy","ECT","Treatment Outcome","Inpatients",[248,249,250,251,252,253,246,254,255,245,29],"flumazenil","benzodiazepine reversal","electroconvulsive therapy","randomized controlled trial","functional magnetic resonance imaging","Autobiographical Memory Test (AMT)","Major Depressive Disorder","Bipolar Disorder","2026-05-27",{"date":258,"type":39},"2026-06-01",{"date":260,"type":39},"2026-01-15",{"date":262,"type":23},"2028-08",{"name":264,"class":46},"Anders Jørgensen",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":141},"100639786","human-neural-correlates-of-multi-timescale-inference-100639786","NCT07606469","Human Neural Correlates of Multi-Timescale Inference","Neuronal Mechanisms of Human Cognition","Inclusion Criteria:\n\n* Epilepsy patients undergoing intracranial electrode monitoring for uncontrolled seizures.\n* no lesions identified in the participants' brains\n* capable of giving consent\n\nExclusion Criteria:\n\n* seizure activity during task recording\n* electrodes in regions of interest are identified to be the seizure focus\n* task performance outside of the normal range as determined from online studies with healthy participants",{"count":273,"type":23},30,"OBSERVATIONAL","Adult epilepsy patients who are undergoing intracranial monitoring will participate in a simple behavioral task during the clinical recording period.",[29,277],"Brain Activity","2026-05-18",{"date":280,"type":39},"2026-05-26",{"date":282,"type":23},"2026-06-15",{"date":284,"type":23},"2028-06-30",{"name":286,"class":46},"University of Colorado, Boulder",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":24,"phases":297,"briefSummary":298,"conditions":299,"keywords":305,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":141},"100638614","the-effects-of-high-intensity-interval-training-on-gait-balance-and-cognitive-functions-in-individuals-with-multiple-sclerosis-100638614","NCT07578740","The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis","Investigating the Effects of High-Intensity Interval Training on Gait, Balance, and Cognition in Individuals With Multiple Sclerosis","HIIT-MS","Inclusion Criteria:\n\n* Diagnosed with Multiple Sclerosis by a neurologist (Hacettepe University Hospitals, Neurology Outpatient Clinic)\n* Age 18 years and older\n* EDSS score between 0 and 4\n* Score of 24 or above on the Standardized Mini Mental State Examination\n* No relapse in the past 3 months\n* Medically stable for at least 6 months\n\nExclusion Criteria:\n\n• Any additional cardiopulmonary, neurological, or systemic disease other than MS",{"count":296,"type":23},40,[26],"This study aims to comparatively investigate the effects of low-volume High-Intensity Interval Training (HIIT) versus Moderate-Intensity Continuous Training (MICT) on gait, balance, cognitive functions, and neurovascular biomarkers (BDNF, VEGF) in individuals with Multiple Sclerosis (MS). This randomized controlled trial will be conducted at Hacettepe University, Faculty of Physical Therapy and Rehabilitation.",[300,301,302,303,29,304],"Multiple Sclerosis","High-intensity Interval Training","Gait","Balance","Biomarkers",[306],"Multiple Sclerosis, High-Intensity Interval Training, HIIT, Gait, Balance, Cognition, BDNF, VEGF, Randomized Controlled Trial",{"date":308,"type":39},"2026-05-20",{"date":310,"type":23},"2026-07",{"date":312,"type":23},"2028-06",{"name":314,"class":46},"Hacettepe University",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":18,"sex":19,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":24,"phases":326,"briefSummary":327,"conditions":328,"keywords":333,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":141},"100589347","acute-impact-of-whey-protein-enriched-milk-fat-globule-membrane-supplementation-on-postprandial-markers-of-heart-and-brain-health-100589347","NCT06953232","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health","Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health in Postmenopausal Women Living With Overweight and at Moderate Risk for Cardiovascular Disease.","Inclusion Criteria:\n\n* Apparently healthy postmenopausal women (not menstruating for 12 or more months)\n* Aged 50 - 75 years\n* BMI: 25 - 40 kg\u002Fm²\n* Moderate CVD risk\n* Recreationally active (\\> 3 x 30 min moderate exercise per week)\n* Understands and is willing and able to comply with all study procedures including eating a high-fat breakfast meal\n* Fluent in written and spoken English\n* Access to, and able to use, the internet\u002Fcomputer\u002Ftablet device\n\nExclusion Criteria:\n\n* Smoking (including vaping)\n* Diagnosed with cardiovascular disease or suffered myocardial infarction \u002Fstroke in the past twelve months\n* Existing or significant past medical history of any medical condition likely to affect the study outcomes e.g., diabetes, digestive, cancer or thyroidal disease, neurological disease (Alzheimer's disease, other form of dementia, mild cognitive impairment), or serious mental illness know to affect cognition (schizophrenia, schizoaffective disorder, bipolar disorder), learning disorders (dyslexia)\n* Early or premature menopause resulting from medical conditions or undergoing surgery\n* Hormone replacement therapy within last 6 months\n* Prescribed medications likely to interfere with study outcomes (including lipid\u002Fcholesterol-lowering medications, including statins; blood thinners, antiplatelets (anticoagulants) such as heparin, etc.; medications for blood pressure; inflammation such as nonsteroidal anti-inflammatory drugs, aspirin, etc.; immune function, or lipid\u002Fcarbohydrate metabolism) or prescribed antibiotics within the last three months\n* Use of antidepressant or anti-anxiety medication if it has changed in the last three months or expected to change within the 3-month study period\n* Taking vitamin, mineral, or fatty acid supplements (e.g., fish oil, calcium) or unwilling stop consuming these for the duration of the study (including sufficient washout period)\n* Working night shifts\n* Inaccessible veins for blood collection via cannulation\n* Unstable weight history (≥3 kg loss or gain in the previous 3 months) or planning or currently on a weight reduction scheme\n* Known allergy or intolerance to study food (including lactose intolerance, dairy, and wheat)\n* Being vegan or any other unusual medical history or diet and lifestyle habits or practices that would preclude volunteers from participating in a dietary intervention or metabolic study\n* Excessive alcohol consumption: \\>21 unit\u002Fwk (i.e., more than 10 and a half pints of beer or 21 small glasses of wine)\n* Currently taking part or have participated in another research study in the last two months (e.g., dietary intervention)","50 Years","75 Years",{"count":325,"type":23},16,[26],"In a single-blind, randomised, placebo-controlled crossover manner, this study aims to assess the impact of a high-fat mixed meal containing a whey protein (WP)-enriched milk fat globule membrane (MFGM) powdered ingredient on markers of heart and brain health in the fed state among middle-to-older-aged, postmenopausal women living with overweight and at moderate risk for cardiovascular disease.\n\nParticipants will attend two \\~8 hour study visits, where they will consume a high-fat meal containing a WP-enriched MFGM powdered ingredient or a placebo WP-based powdered ingredient. Each visit will involve anthropometric measurements and periodic assessments of heart health, including blood pressure and blood vessel stiffness measurements, blood sample collections, as well as computer-based tests measuring mood and cognition (brain function) over a 6-hour postprandial period.",[329,29,330,331,332],"Cardiovascular Diseases","Overweight or Obesity","Postmenopausal Women","Cardiometabolic Risk Factors",[334,335,336,337,338,339,159],"Milk fat globule membrane","Milk polar lipids","triacylglycerol","postprandial","cholesterol","cardiometabolic disease risk",{"date":308,"type":39},{"date":342,"type":39},"2025-09-30",{"date":344,"type":23},"2026-10",{"name":346,"class":46},"Loughborough University",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":358,"conditions":359,"keywords":362,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":4},"100638741","retrospective-analysis-of-cpet-and-cognitive-tests-of-healthy-individuals-treated-with-60-treatment-of-hbot-100638741","NCT07596641","Retrospective Analysis of CPET and Cognitive Tests of Healthy Individuals, Treated With 60 Treatment of HBOT","Retrospective Analysis of Cardiopulmonary Exercise Tests and Cognitive Tests of Healthy Individuals Age 18+ Years, Treated at the Sagol Center for Hyperbaric Medicine and Research With 60 Hyperbaric Oxygen Therapy Treatments.","HBOT","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Completed a full treatment series of 60 hyperbaric oxygen therapy (HBOT) sessions at the Sagol Center\n* Availability of pre- and post-treatment cardiopulmonary exercise testing (CPET) data\n* Availability of pre- and post-treatment cognitive assessment data\n\nExclusion Criteria:\n\n* Inability to complete a maximal CPET test, pre and post HBOT or Missing pre- or post-treatment CPET data.\n* Incomplete HBOT treatment series\n* Missing cognitive assessment data","65 Years",{"count":357,"type":23},1000,"This retrospective observational study evaluates physiological and cognitive changes following a series of 60 hyperbaric oxygen therapy (HBOT) sessions in healthy individuals. Participants underwent treatment five days per week, each session included 90 minutes exposure to 100% oxygen at 2ATA with a five-minute air break every 20 minutes. Pre- and post-treatment data include cardiopulmonary exercise testing (CPET) and standardized cognitive assessments. The study aims to characterize associations between changes in cardiorespiratory fitness and cognitive performance following repeated HBOT exposure in a real-world clinical cohort",[360,361,29],"Hyperbaric Oxygenation","Cardiorespiratory Fitness",[353,363,364,159,365,366,367,368],"VO2MAX","VO2 PEAK","CPET","cardiopulmonary exercise testing","hyperbaric oxygen therapy","HEALTH","2026-05-17",{"date":371,"type":39},"2026-05-19",{"date":373,"type":23},"2026-12-01",{"date":375,"type":23},"2028-03-30",{"name":377,"class":378},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":18,"sex":54,"minAge":355,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":24,"phases":386,"briefSummary":387,"conditions":388,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":141},"100640256","development-of-a-chatbot-supported-personalized-exercise-program-for-older-adults-and-evaluation-of-its-effects-on-cognitive-functions-100640256","NCT07596082","Development of a Chatbot-supported Personalized Exercise Program for Older Adults and Evaluation of Its Effects on Cognitive Functions","Inclusion Criteria:\n\n* Aged 65 years and older\n* Normal or mildly impaired cognitive status\n* Medical condition that does not prevent participation in physical activity\n* Ability to use a smartphone or tablet (for chatbot access)\n* Voluntary participation\n\nExclusion Criteria:\n\n* Moderate to severe dementia\n* Severe depression or serious psychiatric disorders\n* Acute cardiovascular risk\n* Communication difficulties due to significant hearing or visual impairment\n* Regular engagement in structured exercise within the past 6 months (participants in the maintenance phase of exercise behavior)",{"count":5,"type":23},[26],"The purpose of this study is to develop an artificial intelligence-based chatbot application to support exercise behavior in individuals aged 60 and over who do not regularly exercise, and to evaluate its effectiveness. In addition, the study aims to examine the effects of changes in exercise habits on the cognitive (mental) functions of older adults.\n\nIn this study, the impact of a chatbot-supported personalized exercise program on cognitive functions in older individuals will be evaluated. A total of 90 participants is planned for inclusion in this study.\n\nIf you agree to participate in this study, depending on the group you are assigned to, you may receive:\n\n* An artificial intelligence-based chatbot program, along with educational materials about the importance of exercise, or\n* Only educational materials (brochures) prepared by the researchers about the importance of exercise.\n\nAt the beginning of the study, you will be asked to complete a data collection form. The same form will also be administered at week 12 and week 24.\n\nThis form will include:\n\n* Basic information such as your age and gender,\n* Questions about your exercise habits,\n* A brief test to assess your cognitive (mental) functions,\n* Questions evaluating your level of physical activity. The study duration is 24 weeks, including 12 weeks of intervention and 12 weeks of follow-up.",[389,390,29,391,392],"Aged","Exercise","Artificial Intelligence (AI)","Health Behavior","2026-05-12",{"date":371,"type":39},{"date":396,"type":23},"2026-08-01",{"date":398,"type":23},"2026-10-30",{"name":400,"class":46},"Dokuz Eylul University",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":24,"phases":410,"briefSummary":411,"conditions":412,"keywords":437,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":141},"100637694","assessing-the-effects-of-cool-roofs-on-indoor-environments-and-health-in-tavua-fiji-100637694","NCT07592117","Assessing the Effects of Cool Roofs on Indoor Environments and Health in Tavua, Fiji","A Cluster Randomised Controlled Trial (cRCT) Evaluating the Effects of Cool Roofs on Health, Environmental and Economic Outcomes in Tavua, Fiji","Inclusion Criteria:\n\n* Permanent household resident.\n\nExclusion Criteria:\n\n* Roof damage, inaccessible or instability of roof adversely affecting cool roof coating application.\n* Participant unable to provide written\u002Fverbal informed consent.",{"count":409,"type":23},800,[26],"Ambient air temperatures in Fiji are increasing due to climate change. Solutions are needed to build heat resilience in communities and adapt. Sunlight-reflecting cool roof coatings may passively reduce indoor temperatures and energy use to protect home occupants from extreme heat. Occupants living in poor housing conditions in Fiji are susceptible to increased heat exposure.\n\nHeat exposure can instigate and worsen numerous physical, mental and social health conditions. The worst adverse health effects are experienced in communities that are least able to adapt to heat exposure. By reducing indoor temperatures, cool roof use can promote physical, mental and social wellbeing in household occupants.\n\nThe long-term research goal of the investigators is to identify viable passive housing adaptation technologies with proven health benefits to reduce the burden of heat stress in communities affected by heat in Fiji. To meet this goal, the investigators will conduct a cluster-randomized controlled trial to establish the effects of cool roof use on health, indoor environment and economic outcomes in Tavua, Fiji.",[413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,29,431,432,433,434,435,436],"Resting Heart Rate","Blood Glucose Control","Depression","Heat-related Symptoms","Physician Diagnosed Heat-related Illnesses","Food Insecurity","Diet Quality","Health-Related Quality-of-Life","Indoor Thermal Comfort","Coping Ability","Life Satisfaction","Healthcare Provider Utilization","Hospitalization","Systolic Blood Pressure","Diastolic Blood Pressure","Inner Ear Canal Temperature","Dehydration","Sleep Quality","Productivity","Aggression","Indoor Air Temperature","Indoor Relative Humidity","Indoor Heat Index","Household Energy Expenditure",[438,439,440,441,442,415,443,444,445,446,447],"Hot temperature","Humidity","Housing","Heart rate","Cardiovascular","Mental health","Blood glucose","Diabetes","Cool roof","Heat stress","2026-05-11",{"date":278,"type":39},{"date":278,"type":23},{"date":452,"type":23},"2027-09-01",{"name":454,"class":46},"Aditi Bunker",{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":24,"phases":464,"briefSummary":465,"conditions":466,"keywords":471,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":79},"100489612","ifd-survive-functional-efficacy-and-biological-correlates-reconcile-study-100489612","NCT05655390","iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)","The SURVIVE 2 Project: An Extended Cohort Study to Investigate Suicidal Behavior in Spain and the Efficacy of Secondary Prevention Strategies: iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)","RECONCILE","Inclusion Criteria:\n\n* Age over 18 years old\n* Having attempted suicide\n* Provide written informed consent\n* No claustrophobia\u002Fmetallic objects\u002Fimplants\n\nExclusion Criteria:\n\n* Intelligence quotient below 70 and impaired functioning\n* Any medical condition that could affect neuropsychological performance (such as neurological diseases) or a history of head trauma with loss of consciousness\n* Participation in any structured psychological intervention within the past 6 months\n* Patients who received electroconvulsive therapy within the past 6 months\n* Inability to give inform consent",{"count":152,"type":23},[26],"The goal of this clinical trial is to assess the effectiveness of an original intervention 'Functional Recovery in Depression and Suicide Risk Prevention Based on Emotion Regulation and Values: A Group Program' (from the original Spanish version: Programa Grupal De Recuperación Funcional En Depresión Y Prevención De Riesgo Suicida Basado En Regulación Emocional Y Valores) in depressed patients who have recently attempted suicide by improving their psychosocial functioning and therefore enhancing their ability to perform activities of daily living. As secondary objectives, the effectiveness of the intervention will be evaluated by determining cognitive performance (particularly decision-making, inhibition, and attention), quality of life, clinical status, and their relationship with neuroimaging correlates. Main target neuroimaging areas include the orbitofrontal cortex and dorsal prefrontal cortex.",[467,468,29,469,470],"Suicide, Attempted","Functioning, Psychosocial","Neuroimaging","Quality of Lifte",[472,473,474,475,476],"suicide","cognition","neuroimaging","psychosocial functioning","quality of life","2026-05-08",{"date":393,"type":39},{"date":480,"type":39},"2025-09-16",{"date":482,"type":23},"2027-10",{"name":484,"class":46},"Iria Grande",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":54,"minAge":322,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":24,"phases":495,"briefSummary":496,"conditions":497,"keywords":501,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":171},"100613920","the-impact-of-brief-behavioral-treatment-for-insomnia-versus-brief-mindfulness-treatment-on-cognition-and-sleep-health-in-adults-age-50-with-hiv-100613920","NCT07272863","The Impact of Brief Behavioral Treatment for Insomnia Versus Brief Mindfulness Treatment on Cognition and Sleep Health in Adults (Age 50+) With HIV","The Impact of BBTI on Cognition and Sleep Health in Older Adults With HIV","Inclusion Criteria:\n\n* must be age 50 or older\n* have a DSM-5 diagnostic criteria for insomnia including sleep difficulty that occurs at least 3 times per week and has been a problem for at least 3 consecutive months (indicated on the Structured Clinical Interview for Sleep Disorders, SCISD) during telephone screening\n* have a confirmed HIV diagnosis and a prescribed ART regimen for at least 12 months.\n\nExclusion Criteria:\n\n* unable to speak English\n* have a reported or documented (in medical records) diagnosis of AD or dementia\n* have severe neurocognitive impairment (\\>7 errors on the Short Portable Mental Status Questionnaire, SPMSQ) during telephone screening\n* have a history of a stroke\n* currently undergoing radiation\u002Fchemotherapy\n* reports a history of brain trauma with loss of consciousness greater than 30 minutes\n* have a learning disability\n* have a documented diagnosis of sleep apnea (in medical records)\n* reports use of a continuous positive airway pressure machine\n* have been identified as high risk for moderate to severe sleep apnea (Snoring, Tiredness, Observed sleep apnea, Pressure, BMI, Age, Neck circumference, and Gender, STOP BANG ≥ 5) during telephone screening\n* have restless leg syndrome and\u002For have narcolepsy\n* have a documented history of bipolar disorder or psychotic disorder\n* not be receiving efavirenz as part of their current ART regimen","99 Years",{"count":494,"type":23},214,[26],"The goal of this clinical trial is to examine the effects of a telephone-delivered Brief Behavioral Treatment Insomnia (BBTI) versus a Brief Mindfulness Treatment (BMT) on cognitive and sleep outcomes in older adults with HIV. The main questions it aims to answer are:\n\nWhat are the effects of BBTI vs BMT on self-reported and observed sleep outcomes in older adults with HIV and insomnia up to 1-year post-intervention? What are the effects of BBTI vs BMT on self-reported and observed cognitive comes in older adults with HIV and insomnia up to 1-year post-intervention? What is the association between Alzheimer's Disease biomarkers and sleep and cognitive outcomes in older adults with HIV receiving BBTI vs BMT?\n\nParticipants will:\n\n* Complete 4 weeks of telephone-delivered BBTI or BMT\n* Attend baseline, post-intervention, and 1-year post in-person visits for sleep and cognitive assessments\n* Have blood collected at all three time points",[498,29,499,500],"Insomnia","Aging","HIV",[502,473,503,500,504,505,506],"insomnia","older adults","Alzheimer's Disease","brief behavioral treatment","randomized control trial","2026-05-07",{"date":477,"type":39},{"date":510,"type":23},"2026-05",{"date":512,"type":23},"2030-09",{"name":514,"class":46},"University of Alabama, Tuscaloosa",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":4,"eligibilityCriteria":520,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":179,"enrollmentInfo":521,"targetDuration":522,"studyType":274,"phases":4,"briefSummary":523,"conditions":524,"keywords":528,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":536,"leadSponsor":538,"locationsCount":141},"100640763","development-and-psychometric-evaluation-of-the-neurocognitive-upper-extremity-tests-a-reliability-and-validity-study-100640763","NCT07579676","DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE NEUROCOGNITIVE UPPER EXTREMITY TESTS: A RELIABILITY AND VALIDITY STUDY","Inclusion Criteria\n\nGeneral Inclusion Criteria (Both Groups):\n\n* Individuals between the ages of 18 and 40\n* No passive range of motion limitations in the shoulder joint\n* Classified as healthy with no history of injury in the past year according to the Extended Nordic Musculoskeletal Questionnaire\n* Volunteered to participate in the study\\[cite: 1\\].\n\nAthlete Group Specific Criteria:\n\n* Physically active individuals\n* Currently active in sports clubs in Ankara and\u002For applied to the Hacettepe University Department of Sports Physiotherapy and Rehabilitation\n* History of training or physical activity at least three times a week for the past year\n* Participation in recreational or competitive above or below shoulder height sports\n\nControl Group Specific Criteria:\n\n* Healthy individuals who have applied to the Hacettepe University Department of Sports Physiotherapy and Rehabilitation Unit\n* Does not engage in regular physical activity\n* History of training or physical activity fewer than three times a week over the past year\n* No participation in recreational or competitive sports\n\nExclusion Criteria\n\n* Presence of symptomatic upper extremity pathology\n* History of upper extremity and\u002For trunk injury or surgery in the last 12 months\n* History of ongoing neck pain, neurological symptoms in any extremity, or back, hip, or knee pain in the last 12 months\n* Presence of a health condition that could cause a decrease in shoulder strength, such as inflammatory arthritis or neurological disorders\n* Presence of any systemic disease\n* Presence of visual or hearing impairments",{"count":273,"type":23},"1 Week","The goal of this observational study is to develop an upper extremity neurocognitive performance test battery, determine its reliability and validity, and investigate the effect of neurocognitive load on test performance in athletes and healthy volunteers aged 18-40.\n\nThe main questions it aims to answer are:\n\nAre the developed upper extremity neurocognitive tests reliable and valid tool for assessment?\n\nDoes the addition of neurocognitive load significantly affect upper extremity physical performance scores?\n\nAre the neurocognitive performance test results related to shoulder rotator cuff muscle strength, rate of force development, and shoulder function?\n\nResearchers will compare the neurocognitive performance of athletes to healthy non-athlete individuals to see if the test battery can effectively differentiate between these two groups (discriminative validity).\n\nParticipants will:\n\nComplete demographic forms and questionnaires regarding activity level and shoulder function.\n\nUndergo shoulder range of motion and isometric strength\u002Frate of force development assessments.\n\nPerform a battery of 4 neurocognitive tests integrated with a light-based reaction system.\n\nPerform the same functional tests without neurocognitive load to serve as a baseline for comparison.\n\n(Athletes only) Attend additional sessions to evaluate the feasibility of the tests and to assess test-retest reliability with a one-week interval.",[525,526,29,527],"Athletic Performance","Upper Extremity","Physical Functional Performance",[529,530,531,532],"shoulder","Reaction Time","Muscle Strength","Reproducibility of Results","2026-05-05",{"date":393,"type":39},{"date":533,"type":23},{"date":537,"type":23},"2026-07-05",{"name":314,"class":46},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":18,"sex":54,"minAge":20,"maxAge":547,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":556,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":141},"100623790","gutlink4kids-intervention-100623790","NCT07401212","GUTLINK4KIDS Intervention","The Impact of Chronic Consumption of Prebiotics on Cognitive and Affective Outcomes, Gut Microbiome Diversity and Composition in 3-5 Year Olds: a Double-blind Placebo-controlled, Parallel-groups Randomised Controlled Trial","GUTLINK4KIDS","Inclusion Criteria:\n\n* Parents (18 years and over) of generally healthy children aged 3-5-years-old (36-71 months) with lower dietary fibre intake than the recommended daily amount (10.4g\u002Fday in 18-47-month-olds and less than 12.6g\u002Fday in 48-60-month-olds).\n\nExclusion Criteria:\n\n* Children with a significant acute or chronic co-existing illness (including inflammatory bowel disease, functional gastrointestinal disorders, coeliac disease etc, neurodevelopmental, immunological, psychiatric, or metabolic disorders.\n* Children who have taken any pre\u002Fprobiotic supplements or antibiotic treatment within the 4 weeks prior to enrolment.\n* Children with food allergies and intolerances","5 Years",{"count":549,"type":23},106,[26],"This study aims to investigate the chronic effects of prebiotic consumption on cognitive, behavioural and gut microbiome outcomes in children aged 3-5 years.",[553,554,29,555],"Temperament","Sleep","Emotion Regulation",[557,558,559,560,561,562,563,564],"prebiotics","emotion regulation","gut microbiome diversity","children","relative abundance","sleep","internalising symptoms","externalising symptoms","2026-04-27",{"date":567,"type":39},"2026-04-28",{"date":569,"type":39},"2026-03-02",{"date":571,"type":23},"2027-02-01",{"name":573,"class":46},"University of Reading",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":323,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":583,"briefSummary":584,"conditions":585,"keywords":589,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":598,"leadSponsor":600,"locationsCount":4},"100574724","intensive-music-therapy-on-cognitive-function-in-subacute-stroke-rehabilitation-in-malaysia-100574724","NCT06763003","Intensive Music Therapy on Cognitive Function in Subacute Stroke Rehabilitation in Malaysia","Feasibility Randomised Controlled Trial of Intensive Music Therapy on Cognitive Function in Subacute Stroke Rehabilitation in Malaysia","Inclusion Criteria:\n\n* Diagnosed with ischemic or haemorrhagic stroke confirmed by CT scan\n* Duration of stroke within the first 3 months\n* Aged 18 - 75 years old\n* Ability to provide informed consent\n* Understands Bahasa Melayu or English with basic communication abilities to follow instructions during therapy sessions\n* Mild to moderate cognitive impairments with MoCA score of 10-25.\n\nExclusion Criteria:\n\n* Severe aphasia\n* Significant uncorrected hearing or visual impairments preventing engagement in music therapy.\n* Severe or unstable medical conditions (e.g., uncontrolled hypertension or diabetes).\n* Medications that significantly impair cognition or motor function (e.g., high dose sedatives).\n* History of neurological diseases other than stroke (eg, Parkinson's disease).",{"count":582,"type":23},36,[26],"The purpose of this study is to explore whether intensive music therapy can help improve cognitive functions like memory, attention, and decision-making skills in stroke patients who are undergoing rehabilitation.\n\nThis is a feasibility study, meaning it's also designed to see how practical it is to include music therapy as part of stroke rehabilitation. The investigators want to learn how well patients can participate in and stick with this type of therapy, and whether it fits well with other treatments that stroke patients usually receive. By understanding this, the investigators can assess the resources, staff training, and planning needed for music therapy to be part of stroke recovery in the future.\n\nThe study will also help the investigators estimate the effects of music therapy, which will be used to design a larger, more detailed study in the future.",[586,29,587,588],"Rehabilitation","Stroke","Attention",[590,591,592,593,473,594],"Music therapy","randomised controlled trial","rehabilitation","stroke","attention",{"date":596,"type":39},"2026-05-01",{"date":596,"type":23},{"date":599,"type":23},"2026-12-31",{"name":601,"class":46},"University of Malaya",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":18,"sex":54,"minAge":610,"maxAge":56,"enrollmentInfo":611,"targetDuration":4,"studyType":24,"phases":612,"briefSummary":613,"conditions":614,"keywords":618,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":633,"leadSponsor":635,"locationsCount":141},"100635242","etascan-project-etas-project-2-100635242","NCT07550140","ETASCAN Project: ETAS Project 2","The Impact of Chronic Consumption of ETAS® for 12 Weeks on Cognitive, Affective, and Neural Outcomes: A Randomised Parallel Group Placebo-controlled Study","ETASCAN","Inclusion Criteria:\n\n* Aging between 60-80 years old\n* Having normal vision and hearing\n* Having a body mass index between 18.5 and 30\n* Having mild to moderate subjective cognitive complaints\n\nExclusion Criteria:\n\n* Smoking\n* Having food allergies\n* Following restrictive and\u002For unbalanced diets (Appendix 6: Are you vegetarian or vegan? Yes \u002F No; Are you currently on a weight-reducing or other special diet? Yes\u002FNo If 'Yes', please give details.)\n* Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders\n* Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or hypertension or thrombosis related disorders or suffer from thyroid disease\n* Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors\n* Currently consuming prebiotic or probiotic supplements\n* Continuous antibiotic use for \\> 3 days within 1 month prior to enrolment\n* Continuous use of weight-loss drug for \\> 1 month before screening\n* Having a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years\n* History of claustrophobia\n* Fitted with a pacemaker or artificial heart valve\n* Have active implants, such as cochlear, ocular, or penile implant\n* Experience of metal fragments e.g. shrapnel in your eyes or any other part of your body\n* Drug infusion pump installed\n* Have any surgically implanted metal in any part of your body, other than dental fillings and crowns (e.g. joint replacement or bone re-construction)\n* Have had any surgery that might have involved metal implants\n* Current or historical experience of epilepsy\n* Have stimulators for nerves, brain or bone installed\n* Have an intrauterine contraceptive device installed (IUD)\n* Wear transdermal patches containing metal\n* Wear a filling, crown, dental post (entirely within the tooth) associated with root canal treatment, retainer, bridge or braces\n* For scanning, would need to remove coloured contact lenses, nail polish and makeup.\n* Hearing aid wearer\n* Body piercings that you cannot or will not remove for the scanning session\n* Have tattoos or permanent makeup","60 Years",{"count":58,"type":23},[26],"This study aims to investigate the chronic effects of ETAS® on cognitive, affective and neural outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.",[29,615,554,616,215,617],"Affect (Mental Function)","MRI","Magnetic Resonance Spectroscopy",[619,620,621,622,623,624,625,626,627,562,628],"grey matter","brain structure","brain function","neurochemistry","executive function","language","ETAS®","depression","anxiety","gut microbiome","2026-04-17",{"date":631,"type":39},"2026-04-24",{"date":533,"type":23},{"date":634,"type":23},"2027-12-31",{"name":573,"class":46},{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":18,"sex":54,"minAge":179,"maxAge":56,"enrollmentInfo":643,"targetDuration":644,"studyType":274,"phases":4,"briefSummary":645,"conditions":646,"keywords":649,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":655,"leadSponsor":656,"locationsCount":141},"100634487","effects-of-cognitive-dual-task-on-gait-in-parkinsons-disease-100634487","NCT07540325","Effects of Cognitive Dual-Task on Gait in Parkinson's Disease","Investigating the Effects of Cognitive Dual-Task on Gait in Individuals With Parkinson's Disease","Inclusion Criteria for Individuals with Parkinson's Disease:\n\n* A clinical diagnosis of Parkinson's Disease confirmed by a neurologist according to the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria\n* Classified between stages 1 and 3 according to the Modified Hoehn and Yahr Staging Scale\n* Aged between 40 and 80 years\n* A score of at least 21 on the Montreal Cognitive Assessment (MoCA)\n* Ability to walk continuously for at least 10 minutes without interruption and without the use of any assistive walking device\n* Having received at least 5 years of formal education\n\nExclusion Criteria for Individuals with Parkinson's Disease:\n\n* Presence of any neurological disorder other than Parkinson's Disease\n* Presence of any cardiopulmonary or musculoskeletal condition that may impair safe ambulation\n* A score of ≥10 for anxiety and ≥7 for depression on the Hospital Anxiety and Depression Scale (HADS)\n* Presence of visual or auditory impairments that cannot be corrected with assistive devices\n\nInclusion Criteria for Healthy Individuals:\n\n* Aged between 40 and 80 years\n* A score of at least 21 on the Montreal Cognitive Assessment (MoCA)\n\nExclusion Criteria for Healthy Individuals:\n\n* Presence of any neurological disorder\n* Presence of any cardiopulmonary or musculoskeletal condition that may affect safe ambulation\n* A score of ≥10 for anxiety and ≥7 for depression on the Hospital Anxiety and Depression Scale (HADS)\n* Presence of visual or auditory impairments that cannot be corrected with assistive devices",{"count":273,"type":23},"2 Days","The aim of this study is to evaluate gait in individuals diagnosed with PD under tasks involving different cognitive domains, to compare the results with those of age and sex-matched healthy individuals, and to determine which cognitive function has the greatest impact on gait in PD.",[647,29,648],"Parkinson's Disease (PD)","Gait Disorders",[302,156,650,651],"Dual-Task","Parkinson's Disease",{"date":653,"type":39},"2026-04-20",{"date":653,"type":23},{"date":599,"type":23},{"name":657,"class":46},"Gazi University",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":4,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":274,"phases":4,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":141},"100449441","magnesium-and-cognition-after-stroke-100449441","NCT05132517","Magnesium and Cognition After Stroke","Relationship Between Magnesium Concentration in Blood and Kognitive Functions After Stroke","Inclusion Criteria:\n\n* ischemic\u002Fhemmorhagic stroke\n* written consent form\n\nExclusion Criteria:\n\n* pre-existing dementia or cognitive impairment before stroke onset\n* pre-existing mental disorder (depression) or present\u002Fprior long-term treatment (\\> 6 months) with psychotropic drugs\n* pre-existing malign tumor disease\n* participation in another clinical trial within the past 30 days\n* pregnancy or breastfeeding",{"count":666,"type":23},80,"Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients.\n\nLow serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.",[587,29,669,670],"Magnesium","Neurologic Disorder","2026-04-16",{"date":653,"type":39},{"date":674,"type":39},"2022-10-26",{"date":676,"type":23},"2027-09-30",{"name":678,"class":46},"BDH-Klinik Hessisch Oldendorf",{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":18,"sex":54,"minAge":149,"maxAge":200,"enrollmentInfo":685,"targetDuration":4,"studyType":24,"phases":687,"briefSummary":689,"conditions":690,"keywords":693,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":141},"100601342","phase-4-do-antipsychotics-block-insulin-action-in-the-brain-is-it-a-class-effect-100601342","NCT07109245","Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?","Inclusion Criteria:\n\n1. Must be deemed to have the capacity to provide informed consent\n2. Must sign and date the informed consent form\n3. Stated willingness to comply with all study procedures;\n4. Age: 18-35\n5. Body Mass Index (BMI) 18.5-24.9 kg\u002Fm2\n6. Both sexes\n\nExclusion Criteria:\n\n1. History of psychiatric illness, including any substance use (screened using the Mini International Neuropsychiatric Interview (MINI))\n2. Pre-diabetes or diabetes (fasting glucose ≥6.0 mmol\u002FL, HbA1c\\>6% or use of anti-diabetic drug),\n3. Evidence of impaired insulin sensitivity, assessed using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≥2.5\n4. Family history of diabetes in a first degree relative (parent or sibling)\n5. Use of weight reducing agents\n6. History of kidney or liver disease\n7. History of cell blood disorders\n8. Irregular menstrual cycles (e.g., menstruation occurs less than 21 days or more than 35 days apart, or not having menstruated for three months (or 90 days), or conditions such as endometriosis or polycystic ovary syndrome (PCOS) or prior surgical interventions such as a hysterectomy or oophorectomy)\n9. Current use of hormonal birth control (e.g., pill, patch, hormonal intrauterine device \\[IUD\\], ring). Participants must have had at least 2 regular menstrual cycles following the discontinuation of hormonal birth control \\[50\\]\n10. Current use of progesterone, estrogen, testosterone, or fertility treatment.\n11. Pregnant, gave birth in the last year, or breastfeeding. Participants must have at least 3 regular menstrual cycles post-breastfeeding before beginning the study.\n12. Major medical or surgical event within the last 6 months\n13. Contraindications for MRI, including metal implants, pacemakers, cochlear implants, claustrophobia, weight \\>250 lbs\n14. Any contraindications to the investigational products as listed in the product monographs including known hypersensitivity to the drug or the excipients of the product (note: enzymatic lactose intolerance is NOT exclusionary),\n15. Any medications that increases risk of hypoglycemia or could contribute to hyperglycemia\n16. Any medical conditions that constitute as a warning\u002Fprecaution for haloperidol, lorazepam, benztropine, or insulin.\n17. Use of any of the prohibited medications listed in the product monograph of haloperidol, lorazepam, benztropine, or insulin (Pheochromocytoma, barbiturates, and narcotics are exclusionary, any use of painkillers and antihistamines must be reviewed by PI but are not exclusionary",{"count":686,"type":23},35,[688],"PHASE4","This study aimed at helping researchers understand how a medication called haloperidol can affect insulin action in the brain. Insulin is a hormone in the body that controls sugar levels in part by lowering the amount of glucose produced by the liver. After eating a meal, insulin levels go up in both the blood and the brain. Insulin in the brain has also been shown to affect the way the brain works and processes information (also known as \"cognition\"). Haloperidol, is an antipsychotic medication used to treat a variety of disorders such as schizophrenia spectrum disorders, bipolar disorder, and major depressive disorder, but long-term use can have metabolic side effects, like weight gain, type 2 diabetes, and cardiovascular disease. The purpose of this study is to investigate how antipsychotic medications, such as haloperidol, which carries the risk of metabolic changes, might interrupt the effect of insulin action in the brain. This will help researchers learn how to potentially reduce metabolic risk for people who take these kinds of medications in the future.",[691,692,29],"Brain Insulin Sensitivity","Healthy Controls",[691,694,695,29,616],"Healthy Control Study","Haloperidol","2026-03-30",{"date":698,"type":39},"2026-04-02",{"date":700,"type":39},"2025-12-11",{"date":702,"type":23},"2028-12",{"name":704,"class":46},"Centre for Addiction and Mental Health",{"id":706,"slug":707,"hasResults":12,"nctId":708,"briefTitle":709,"officialTitle":710,"acronym":4,"eligibilityCriteria":711,"healthyVolunteers":18,"sex":54,"minAge":355,"maxAge":4,"enrollmentInfo":712,"targetDuration":4,"studyType":24,"phases":713,"briefSummary":714,"conditions":715,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":719,"lastUpdatePostDateStruct":720,"startDateStruct":722,"completionDateStruct":724,"leadSponsor":726,"locationsCount":141},"100631840","effects-of-breathing-exercises-on-cognition-in-older-adults-100631840","NCT07505914","Effects of Breathing Exercises on Cognition in Older Adults","Comparing Different Breathing Exercises Added to Balance Training on Cognitive and Functional Outcomes in Elderly Population","Inclusion Criteria:\n\n* Adults aged 65 years and older\n* Able to walk independently\n* Suitable for light to moderate physical activity\n* Willing and able to attend 2 sessions per week for 8 weeks\n\nExclusion Criteria:\n\n* Underwent surgery within the last 6 months\n* Currently participating in another structured rehabilitation program\n* Neurological disorders that significantly restrict mobility (e.g., Parkinson's disease, stroke)",{"count":296,"type":23},[26],"The goal of this interventional clinical trial is to investigate the effects of breathing exercises added to balance training on cognitive function in individuals aged 65 years and older.\n\nThe main questions it aims to answer are:\n\nDo breathing exercises affect cognition? Do different breathing exercises affect cognition in different ways?\n\nResearchers will administer two different breathing protocols and evaluate cognition before and after each protocol.\n\nParticipants will take part in an 8-week program consisting of sessions that include 30 minutes of balance-based exercises and 15 minutes of breathing exercises. Sessions will be held twice weekly under the supervision of a physical therapist.",[716,29,717,718],"Older Adults (65 Years and Older)","Balance Control in Elderly","Fall Prevention in Healthy Aging","2026-03-29",{"date":721,"type":39},"2026-04-01",{"date":723,"type":23},"2026-03-20",{"date":725,"type":23},"2026-12",{"name":727,"class":46},"Istanbul University - Cerrahpasa",{"id":729,"slug":730,"hasResults":12,"nctId":731,"briefTitle":732,"officialTitle":732,"acronym":733,"eligibilityCriteria":734,"healthyVolunteers":18,"sex":54,"minAge":735,"maxAge":736,"enrollmentInfo":737,"targetDuration":4,"studyType":24,"phases":739,"briefSummary":740,"conditions":741,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":744,"lastUpdatePostDateStruct":745,"startDateStruct":747,"completionDateStruct":749,"leadSponsor":751,"locationsCount":141},"100424742","modeling-the-effects-of-chronic-marijuana-use-on-neuroinflammation-and-hiv-related-neuronal-injury-100424742","NCT04810858","Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury","CHI","Inclusion Criteria:\n\n* verified HIV status\n* Current marijuana use (MJ+ groups only)\n* No current marijuana use (MJ- groups only)\n* current engagement in HIV care (HIV+ participants only)\n* receipt of cART as first-line of treatment (HIV+ participants only)\n* stable cART regimen (HIV+ participants only)\n* undetectable HIV RNA viral load for \\>1 year (HIV+ participants only)\n\nExclusion Criteria:\n\n* Lifetime abuse for any illicit drug other than marijuana\n* \\\u003C9th grade education; illiteracy or lack of fluency in English\n* history of moderate or severe head trauma\n* unstable or serious neurological disorders\n* severe mental illness\n* systemic autoimmune diseases\n* immunotherapy\n* MRI contraindications","25 Years","59 Years",{"count":738,"type":23},220,[26],"This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.",[742,500,743,29,469],"Cannabis","Inflammation","2026-03-27",{"date":746,"type":39},"2026-03-31",{"date":748,"type":39},"2021-08-18",{"date":750,"type":23},"2027-05-31",{"name":752,"class":46},"Wake Forest University Health Sciences",{"id":754,"slug":755,"hasResults":12,"nctId":756,"briefTitle":757,"officialTitle":758,"acronym":759,"eligibilityCriteria":760,"healthyVolunteers":12,"sex":54,"minAge":149,"maxAge":4,"enrollmentInfo":761,"targetDuration":4,"studyType":24,"phases":763,"briefSummary":764,"conditions":765,"keywords":772,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":777,"lastUpdatePostDateStruct":778,"startDateStruct":779,"completionDateStruct":780,"leadSponsor":782,"locationsCount":4},"100631702","the-effect-of-remotely-delivered-pilates-on-physical--and-psychological-outcomes-in-individuals-with-multiple-sclerosis-100631702","NCT07504120","The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis","Does Remotely Delivered Pilates Influence Physical and Psychological Outcomes in Individuals With Multiple Sclerosis?","MS","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-reported diagnosis of multiple sclerosis by a neurologist\n* Relapse-free for the past 30 days before screening\n* Able to speak and read English as the primary language\n* Access to the internet and e-mail,\n* Ability to use Zoom, and willingness to complete testing sessions and questionnaires\n* Ambulatory without an assistive device (for example, cane)\n* Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)\n* Insufficiently active, defined as a score \\\u003C 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)\n* Adequate visual ability and literacy to read materials printed in 14-point font\n* Currently treated with a disease-modifying therapy\n\nExclusion Criteria:\n\n* Pregnant\n* Elevated risk for strenuous or maximal exercise, defined as more than one \"Yes\" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening",{"count":762,"type":23},50,[26],"Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.\n\nObjective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \\& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.\n\nAim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \\& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.\n\nHypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.\n\nHypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \\& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.",[300,766,767,303,768,769,770,415,29,771],"Pilates Exercise","Walking","Fatigue in Multiple Sclerosis","Pain Management","Quality of Life","Fatigue",[773,774,771,29,775,767,415,303,776],"multiple sclerosis","Pilates","Quality of life","Pain","2026-03-25",{"date":746,"type":39},{"date":258,"type":23},{"date":781,"type":23},"2027-12-01",{"name":783,"class":46},"University of Illinois at Chicago"]